Synopsys Gains 0.25% with 193rd Trading Volume Rank as Earnings Outperform and Analysts Raise Targets

Generated by AI AgentAinvest Market Brief
Friday, Aug 15, 2025 8:19 pm ET1min read
SNPS--
Aime RobotAime Summary

- Synopsys rose 0.25% to $618.98 on August 15, 2025, with $540M trading volume ranking 193rd.

- Institutional ownership at 85.47% grew as Vanguard and Pictet increased stakes; analysts raised price targets to $660-$620.

- Q2 earnings of $3.67/share beat estimates, showing 10.3% YoY revenue growth and 34.77% net margin.

- Despite $13M in insider sales, the stock supported a $10,720 profit for short-term traders since 2022.

On August 15, 2025, SynopsysSNPS-- (NASDAQ: SNPS) closed at $618.98, rising 0.25% with a trading volume of $540 million, ranking 193rd in daily activity. Institutional ownership remains strong, with 85.47% of shares held by major investors, including increased stakes from Vanguard and Pictet Asset Management. Recent filings revealed MeridianMRBK-- Wealth Management LLC acquiring 1,221 shares valued at $524,000 in Q1 2023.

The company’s latest quarterly earnings showed $3.67 per share, surpassing estimates and reflecting a 10.3% year-over-year revenue increase. Analysts have upgraded price targets, with Piper SandlerPIPR-- and Goldman SachsGS-- setting new highs at $660 and $620 respectively. Despite insider sales totaling $13 million over three months, the stock’s robust financial metrics—including a 34.77% net margin—highlight underlying strength.

A strategy of buying the top 500 stocks by daily trading volume and holding for one day from 2022 to present yielded $10,720 in total profit. The approach experienced steady gains with occasional market-driven fluctuations, underscoring the stock’s role in short-term trading dynamics.

Market Watch column provides a thorough analysis of stock market fluctuations and expert ratings.

Latest Articles

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet